P4, N=100, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting --> Recruiting | Trial completion date: Feb 2025 --> Apr 2029 | Trial primary completion date: Feb 2025 --> Apr 2029

P=N/A, N=90, Not yet recruiting, Assiut University

The bovine corpus luteum (CL) is critical for pregnancy establishment and maintenance via progesterone (P4) secretion...Furthermore, Co-culture with SV40T-IBLC significantly enhanced the viability of bovine endometrial epithelial cells (BEEC) by 34.2% after 72 h of co-incubation (p < 0.01), increased intracellular lipid droplet abundance of BEEC, and upregulated the mRNA expression of endometrial receptivity-related genes including EGF and LIF, with no significant alteration in BEEC apoptosis rate. In conclusion, this immortalized cell line retains core functional characteristics of PBLC, providing a stable, homogeneous in vitro model for bovine reproductive research.

P2, N=44, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Feb 2027

To explore P4-induced metabolic changes before and after the onset of HGSC, we analyzed serum samples from DKO mice treated with P4 or mifepristone, an inhibitor of P4 signaling, at premalignant and early tumor stages. Conversely, at this same stage, the targeted dataset showed notable increases in estrogens and glucocorticoids, while higher corticosterone levels were detected as HGSC began to develop. Overall, this study highlights the disruption of specific metabolites, phospholipid classes, and steroid hormones, in relation to HGSC tumor development under P4 treatment, suggesting their potential roles in OC development.

P2, N=120, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2026 --> Dec 2025

P4, N=642, Not yet recruiting, Medical University of South Carolina | Initiation date: May 2026 --> Aug 2026

P3, N=214, Not yet recruiting, University Hospital, Montpellier

Despite using progestogens (micronized progesterone and dydrogesterone), associated with the lowest risk, a slight increase in risk is still observed over 6 years of treatment. Various scientific societies have based their recommendations on the limitations of menopausal hormone therapy, depending on risk category. Discussions with the patient and lifestyle improvements can help modulate and tailor these recommendations.

The AMPK-FOXO1-CALB2 axis mediates MET-induced mitochondrial dysfunction and apoptosis, providing a mechanistic basis for MET to overcome progesterone resistance in ECC.

Combined use of androstenes and progestogens may provide therapeutic benefits for acute and chronic inflammatory conditions, with possible additive or synergistic effects when used sequentially or simultaneously.

Altogether, these findings highlight the critical role of adrenal- dependent androgen synthesis, particularly via progesterone, in driving the sclerotic CRPC in bone. Our findings suggest that a comprehensive blockade of adrenal contribution is essential to prevent the sclerotic bone response associated with CRPC.